A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Eosinophilic Esophagitis

In brief

This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.

Key facts

Study ID
NCT04322708
Run by
Allakos Inc.
People needed
277
Starts
2020-07-06
Expected to finish
2022-01-18
Last updated by the study team
2024-01-02

Who can join

Age: 12 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.